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S U M M A R Y
Background: In India, the enzyme immunoassay (EIA)/rapid test is used for screening and conﬁrmatory
antibody testing of HIV infection, and all HIV reactive samples are further conﬁrmed by two other rapid
tests working on different principles; however, Western blotting (WB) and immunoﬂuorescence (IF)
assays are not routinely performed in this country.
Methods: A total of 2104 sera from Indian subjects were tested for the presence of HIV-1 antibody using
EIA/rapid tests, according to the guidelines of the National AIDS Control Organization of India, and were
also subjected to IF test using L-2 cells persistently infected with defective HIV-1. WB and a nested
reverse transcriptase polymerase chain reaction (RT-PCR) were performed on discrepant samples.
Results: IF results were 100% concordant with EIA/rapid tests for 212 HIV-1-positive samples and 1889
HIV-1-negative samples. Interestingly, three (0.14%) samples negative by EIA/rapid tests were weakly or
moderately positive (1+/2+) by IF test. All three of these samples were conﬁrmed to be negative by WB
(reactive with Gag/Pol, but not with Env), but positive by RT-PCR with primers targeting the C2–V5
fragment of the env gene. These three samples were from individuals who voluntarily reported for HIV
testing because of high-risk practices, and they may have been at an early stage of HIV infection.
Conclusions: These results conﬁrm that the IF test using L-2 cells is a sensitive and speciﬁc alternative
method for conﬁrmation of HIV-1 infection and could be included in the diagnostic algorithm in
reference laboratories in developing countries.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The human immunodeﬁciency virus (HIV) epidemic continues
to be a burden worldwide, especially in developing countries.1
Though there has been dramatic progress in the diagnostic
methodologies, the detection of antibodies continues to be the
mainstay of diagnosis in most of these countries. Serologic assays
for the detection of anti-HIV antibodies, rapid HIV tests, and
enzyme immunoassays (EIAs) are universally used for initial
screening. The currently available commercial rapid or EIA kits are
more speciﬁc than previous ones, but they still produce false-
positive reactions, necessitating the use of a conﬁrmatory test. The
US Centers for Disease Control and Prevention (CDC) recommend
that all reactive screening tests be conﬁrmed by supplemental
testing using either a Western blot (WB) or indirect immunoﬂuo-
rescence (IF) assay.2 Additionally, if the WB or IF assay is negative* Corresponding author. Tel.: +81 6 6879 8307; fax: +81 6 6879 8310.
E-mail address: ikuta@biken.osaka-u.ac.jp (K. Ikuta).
1201-9712/$36.00 – see front matter  2010 International Society for Infectious Disea
doi:10.1016/j.ijid.2010.08.004or indeterminate, conﬁrmatory testing should be repeated with a
follow-up blood specimen collected 4 weeks after the initial tests
to rule out specimen mix-up or early seroconversion.2
The WB technique provides a speciﬁc approach for HIV
serology. However, despite the proven advantages of WB, the
use of this test has been limited to only a few reference
laboratories. The reasons for the restricted use of WB include
the technical complexity of the procedure, i.e., developing in-house
strips, time-consuming procedures, high cost, and the requirement
of technical expertise and specialized equipment and reagents. A
number of HIV-1/2 WB strips are commercially available that are
more rapid (16–20 h) than in-house tests and are easy to perform
without any special equipment, however these kits remain cost-
prohibitive. Furthermore, WB usually yields a high number of
indeterminate results due to the restrictive criteria that require the
presence of Gag, Pol, and Env antibody, usually lacking in many
AIDS patients; this complicates the accurate interpretation of
results, which must be followed by further serological examina-
tions, thus further increasing testing costs, time, and technical
requirements.ses. Published by Elsevier Ltd. All rights reserved.
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used conﬁrmatory test in many laboratories. The primary
advantages of the IF assay are that it is technically simple, more
convenient, less expensive, and more rapid than WB. Commercial
WB tests usually require overnight incubation for optimal results,
while commercial IF assays can be performed within 2 h.
Additionally, cells are maintained by dilution passage every 4
days, which takes less than 5 min. Moreover, the use of an
uninfected cell control ensures high assay speciﬁcity by easily
differentiating non-speciﬁc staining from speciﬁc staining.
The source of viral antigen in HIV IF assays has commonly been
continuous lymphoid cell lines such as H9 or HUT783 and non-
lymphoid cell lines such as the T4 HeLa cell line.4,5 In this study, a
previously developed human T-cell line persistently infected with
defectiveHIV-1 (L-2 cell clone)6wasused inan IFassay systemalong
withMT-4cells as control cells. Theadvantageofusing this cell clone
is that L-2 cells show exceptionally strong HIV-1 antigen expression
compared with other persistently HIV-1 infected human T-cell
lines7 and continuously produce non-infectious, reverse transcrip-
tase-negative doughnut-shaped particles.6 The goal of the present
studywas to explore the suitability of L-2 cells as a potentially useful
source of viral antigens in IF assays for HIV conﬁrmatory testing.
2. Methods
2.1. Serum samples
From October 2006 to May 2008, 2104 serum samples were
tested. Sera were obtained from 954 consecutive diagnostic[(Figure_1)TD$FIG]Figure 1. Diagnostic algorithm used for HIV positivity conﬁrmation. On the left-hand side
testing guidelines. On the right-hand side, the diagnosis procedure using the IF assay for tspecimens received for HIV antibody testing from individuals
attending the Integrated Counseling and Testing Centre (ICTC) of a
tertiary care hospital in India and 1150 consecutive samples
collected during a sentinel surveillance program. Out of the 1150
samples, 400 were from antenatal clinic attendees and 250 each
were from female sex workers, intravenous drug users, and men
having sex with men (MSM). Each patient gave written informed
consent for study participation and received pretest counseling
prior to sample collection, in accordance with the guidelines of the
National AIDS Control Organization (NACO), India.8
2.2. Routine HIV serology
In this study, screening and conﬁrmatory antibody testing for
HIV infection was performed as recommended by NACO, India,
following a serial testing strategy (Figure 1). Brieﬂy, the samples
were initially screened for HIV antibody by EIA/rapid test, i.e.,
CombAids-RS (Span Diagnostics Ltd, India; Dot Immunoassay)/
Microlisa-HIV (J. Mitra & Co. Pvt. Ltd, India; Indirect ELISA
principle). All samples found negative by the ﬁrst screening test
were reported negative. To reduce the costs of HIV testing as
recommended by the World Health Organization,9,10 all the HIV
reactive samples were further conﬁrmed by two more rapid tests
working on different principles, such as ACON-HIV (Rapid
Diagnostic Pvt Ltd, India; Tri-line rapid chromatographic immu-
noassay), Capillus test (Trinity Biotech plc, Bray, Co. Wicklow,
Ireland; agglutination test), or Retroquic-HIV (Qualpro Diagnos-
tics, India; rapid immunoconcentration test). Samples reactive in
all three assays were reported as positive for HIV antibody. For, EIA/rapid tests were performed as per National AIDS Control Organization, India HIV
he same samples is shown, including follow-up conﬁrmation using WB and RT-PCR.
Table 1
Results of EIA/rapid tests and IF assay in different subject groups
Subject group Number
tested
Number reactive
by EIA/rapid test
Number
reactive by
IF assay
Integrated counseling and
testing centre
954 202 205
Antenatal clinic 400 1 1
Female sex workers 250 3 3
Intravenous drug users 250 2 2
Men having sex with men 250 4 4
Total 2104 212 215
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screening and then conﬁrmation of the positive samples by one
test.8 All the kits used for the detection of HIV antibody were
approved and supplied by the Delhi State AIDS Control Society,
India. In India, WB testing and IF assays are not routinely
performed and are restricted to specimens with atypical serologi-
cal proﬁles (discordant results by three EIA/rapid tests).
2.3. Cell lines
The uninfectedMT-4 human T-cell line and the infected L-2 cell
line were used. MT-4 was the parental cell line used for the
preparation of the L-2 cell clone thatwas persistently infectedwith
the defective HIV-1 subtype B LAI strain.6 These cell lines were
maintained at the Department of Virology, Research Institute of
Microbial Diseases, Osaka University, Japan. L-2 and MT-4 cells
were propagated by incubation in RPMI-1640 supplemented with
5–10% heat-inactivated fetal bovine serum at 37 8C in a CO2
incubator. Cells were cultured at 5  105/ml until the cell density
reached 2–3  106/ml on the 4th day post-incubation. Cells were
maintained by subdividing 1:4 (v/v) in fresh medium every 4 days.
2.4. Slide preparation
The cells were harvested, washed with phosphate-buffered
saline (PBS), and suspended in PBS at 1  106 cells/ml. One part L-2
cell suspension was mixed with three parts uninfected MT-4 cell
suspension. The MT-4 and L-2 cells were smeared on a 12-well
glass slide (Flow Laboratories). Approximately 5  103 cells (5ml
of a 1  106 cells/ml suspension) were placed in each well. The
slides were air-dried and ﬁxed in cold acetone for 10 min at 4 8C.
The slides were packed in heat-sealed plastic bags and stored at
20 8C until use.
2.5. IF assay procedure
All patient sera were heat-inactivated at 56 8C for 30 min and
diluted 1:100 in PBS. Ten microliters of each diluted serum were
applied to wells and incubated in a humid chamber at 37 8C for
30 min. PBS and HIV-positive and HIV-negative sera were used as
internal controls each time. After washing three times with PBS at
room temperature, 10 ml of the ﬂuorescein isothiocyanate (FITC)-
conjugated goat anti-human IgG (Jackson ImmunoResearch
Laboratories Inc.) was applied to the wells; these were again
incubated at 37 8C for 30 min. The slides were rinsed three times
with PBS and mounted in 90% glycerol in PBS and read
independently by two trained persons, who were blinded to
serological results, under a ﬂuorescence microscope (Labophot-2;
Nikon, Tokyo, Japan). This test was performed as a single assay
(without replicates). Any ambiguous or discordant samples were
retested in duplicate.
2.6. Interpretation of IF assay results
The typical cytoplasmic staining patterns of L-2 cells were
graded from 0 to +4 according to the intensity of FITC in
approximately 25% of L-2 cells present in a monolayer of the
HIV-infected wells (approximately 1.25  103 L-2 cells/well), as
described elsewhere.11 A false-positive reaction was detected
when both the L-2 and MT-4 cells were stained.
2.7. Western blot
WB was performed on the samples with discordant rapid test
and IF assay results.WB testingwas performedwith theHIVWBkit
from J. Mitra & Co. Pvt Ltd, India, following the manufacturer’sinstructions. Results were interpreted according to the criteria
suggested by the manufacturer; interpretation criteria for a
positive test were 2 Env + 1 Gag  1 Pol band and for an
indeterminate test were 1 Env  Gag  Pol or Gag  Pol or only
Gag or only Pol.
2.8. RNA extraction and envelope PCR ampliﬁcation
Viral RNA was extracted from the patient serum samples using
the QIAamp blood kit (Qiagen, Chatsworth, CA, USA). A reverse
transcriptase polymerase chain reaction (RT-PCR) was performed
to amplify a 708-base pair C2–V5 fragment of the env gene, using
previously described primer sets.12 We used an infectious
molecular clone of Indian subtype C HIV-1 – Indie-C1 – as a
positive control.13 Brieﬂy, viral RNA was initially reverse-
transcribed at 50 8C for 50 min using the ThermoScript kit
(Invitrogen, Carlsbad, CA, USA). Subsequently, for the cDNA
ampliﬁcation, the EX Taq PCR kit (Takara, Kyoto, Japan) was used
as per the manufacturer’s instructions. A nested PCR reaction
protocol was used. In the ﬁrst round reaction, the forward primers
were ED31 (CCTCAGCCATTACACAGGCCTGTCCAAAG) and BH2
(CCTTGGTGGGTGCTACTCCTAATGGTTCA). Five microliters of the
ﬁrst round reaction product was subjected to a second round of
ampliﬁcation, with the primers DR7 (TCAACTCAACTGCTGT-
TAAATGGCAGTCTAGC) and DR8 (CACTTCTCCAATTGTCCCTCA-
TATCTCCTCC). The cycling conditions for both ampliﬁcations
consisted of initial activation at 94 8C for 2 min, followed by 35
cycles of 94 8C for 15 s, 56 8C for 30 s, and 72 8C for 45 s, with a ﬁnal
extension at 72 8C for 7 min. Ampliﬁed PCR products were
visualized by electrophoresis in 1% agarose gel.
3. Results
Out of the 2104 samples, 1892 tested HIV-negative and 212
HIV-positive by EIA/rapid test (Table 1). Speciﬁc IF patterns of
reactivity toHIV antigenswere clearly demonstrated in all 212 sera
positive by EIA/rapid test, as well as the positive control serum
from an HIV-1-infected individual (Figure 2, G). Of the 212 serum
samples, 184 were IF-strongly positive (3+ or 4+), 21 were
moderately positive (2+), and seven were weakly positive (1+).
These seven samples weakly positive (1+) at a dilution of 1:100,
were strongly positive (3+ or 4+) at a dilution of 1:20, which gave
negative staining in MT-4. In addition, three sera (termed X, Y, and
Z) from the ICTC that were negative by EIA/rapid test, were also
weakly to moderately positive (one sample 2+, two samples 1+) by
IF assay (Figure 2, A, C, and E). The positive reactions of the three
sera by IF were conﬁrmed on repeat testing. We also observed that
another nine (seven from the ICTC and two from MSM) of the sera
negative by EIA/rapid test were also weakly positive by IF.
However, all the sera showed negative reactions on repeat testing
with the IF test. Hencewe concluded that the results were negative
in these nine serum samples. The other 1880 sera negative by EIA/
rapid test were also negative by IF.
[(Figure_2)TD$FIG]
Figure 2. IF of the three discordant serum samples. The three serum samples (X, Y, and Z) showed discordant results: negative by EIA/rapid test but positive by IF assay. The L-
2 cells (A, C, E, G, and I) and uninfectedMT-4 cells (B, D, F, H, and J) as negative control were similarly reactedwith 1:100 dilutions of sera fromX (A and B), Y (C and D), and Z (E
and F), and negative control serum from a healthy individual (G and H) and a positive control serum from an HIV-1-infected individual (I and J).
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negative by WB because reactions with Gag and Pol proteins were
observed, however there were no reactions with Env proteins in
any of the three serum samples (Figure 3, A). When we subjected
these three plasma samples to RT-PCR analysis for the detection of
HIV-1 RNA in plasma, it was found that all the samples were
positive (Figure 3, B).4. Discussion
The IF assay has been used successfully in diagnostic laborato-
ries for three decades and has proven to be an acceptable test for
the detection of anti-HIV-1 antibodies.14–20 We have described
here the performance of one such IF assay using L-2 cells as an
alternative antigen source, within the context of a state reference
[(Figure_3)TD$FIG]
Figure 3. Conﬁrmation of the three discordant serum samples by WB and RT-PCR.
The three serum samples (X, Y, and Z) were subjected to WB (A) and nested RT-PCR
(B). ForWB: lane 1, X serum; lane 2, Y serum; lane 3, Z serum; lane 4, reagent blank
as a negative control; lane 5, Indie-C1 as a positive control.
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suspected cases of HIV infection.
The IF assay was compared with EIA/rapid tests for the ability
to detect antibodies to HIV. A total of 2104 specimens were
tested by both systems. When both assays were used, 212 serum
samples were positive and 1889 samples were negative (99.86%
concordance). Only three (0.14%) specimens gave discrepant
results, i.e., IF produced weakly to moderately positive results,
which required retesting for resolution. The three discrepant
samples were also negative on WB but were positive on PCR.
These samples were from direct walk-in, asymptomatic individ-
uals attending the ICTC for HIV testing, who were involved in
high-risk practices. The IF assay and PCR positivity in these cases
denotes an early stage of infection, indicating the high
sensitivity of the IF assay in comparison to WB. No false-
negative results were observed with the IF assay on single
testing of 212 HIV-positive sera. The IF assay was found to be
almost as sensitive and speciﬁc as ELISA as reported in earlier
studies.17,18 However, in this study it was observed to be slightly
more sensitive and equally speciﬁc to the EIA/rapid test.
Lennette et al.17 tested 181 sera by both IF assay and ELISA
and there were 91 positive and 85 negative sera. They reported
that an additional ﬁve sera were positive by ELISA only. All ﬁve
were shown to be negative on retesting and were considered as
false-ELISA positives. Gallo et al.18 observed 100% agreement
between EIA and IF on 142 serum specimens from homosexual
men and on 88 sera from frank AIDS cases.
It has been reported that if the IF assay is performed in a
diagnostic laboratory with experience in IF, the false-positive rate
should be less than 1% on initial testing and should approach zero
on repeat testing.14 In the present study no false positivity was
observed.
Additionally, the cost–performance ratio must be considered
when deciding which conﬁrmatory test to use for the evaluation of
sera that show discrepant results in two screening assays. Previous
studies21,22 have suggested both WB and IF to have comparable
performance characteristics, but conﬁrmation by IF assay can be
implemented at a cost that is on average ﬁve times less than WB.
Therefore IF constitutes a better cost–performance alternative to
WB, especially in the case of healthcare centers in India where
immunoﬂuorescentmicroscopy is routinely done to evaluate other
infectious disease, and thus can be implemented at no additional
cost.To conclude, the evaluation of IF using HIV-1-infected L-2 cells
as a source of antigen shows it to be a rapid, reliable, and less
expensive test. As it was observed to be slightly more sensitive
than WB after evaluating the results of discordant samples with
PCR, we feel that it is well suited for use in reference laboratories
for conﬁrmation of HIV infection, replacing or complementingWB.
However, its sensitivity for the diagnosis of early infection needs to
be evaluated further. The IF assay reagents are simple to prepare
within the capacity of most reference laboratories. The reagents
are also quite stable with a shelf life of many months.
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